Abstract
AimTo evaluate short-term and long-term outcomes of subretinal coapplication of recombinant tissue plasminogen activator (rtPA) and bevacizumab followed by intravitreal injections of bevacizumab or ranibizumab for neovascular age-related macular degeneration...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have